- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02257528
Nivolumab i behandling av pasienter med vedvarende, tilbakevendende eller metastatisk livmorhalskreft
En fase II-evaluering av Nivolumab, et fullt humant antistoff mot PD-1, i behandling av vedvarende eller tilbakevendende livmorhalskreft
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To assess the antitumor activity (proportion of objective response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of nivolumab with objective tumor response in patients with persistent, recurrent or metastatic carcinoma of the cervix.
II. To determine the nature and degree of toxicity of nivolumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) in patients with persistent, recurrent or metastatic carcinoma of the cervix.
SECONDARY OBJECTIVES:
I. To estimate the duration of progression-free survival (PFS) and overall survival (OS).
TERTIARY OBJECTIVES:
I. To systematically evaluate programmed cell death (PD)-1 and B7 homolog 1 (B7-H1) (i.e., PD-1 ligand) expression in tumor infiltrating lymphocytes (TILs) and cervical cancer cells and explore their correlations with objective response, PFS, and OS in nivolumab-treated patients with PD-1 and B7-H1 scoring results.
II. To explore the composition of immune infiltrates in tumor specimens/biopsies from primary and/or metastatic/recurrent sites with selected markers including (but not limited) to cluster of differentiation (CD)4+, CD8+, forkhead box P3 (FoxP3), CD25, lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin mucin-3 (TIM-3), and inducible T-cell co-stimulator (ICOS) and their correlations to objective response, PFS and OS in nivolumab-treated patients.
III. To evaluate human papillomavirus (HPV) status and to explore the changes of pre- and post-immune therapy responses to HPV16/18/31/35/45 E7 antigens in patients peripheral blood lymphocytes (PBL) and serum using proliferative and interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) (cellular immunity) and serological (enzyme-linked immunosorbent assay [ELISA]) assays.
IV. To explore the levels of circulating tumor cells (CTCs) pre-treatment and at 8 and 12 weeks and their association with patient outcome.
OUTLINE:
Patients receive nivolumab intravenously (IV) over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forente stater, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Forente stater, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Forente stater, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Forente stater, 99504
- Anchorage Radiation Therapy Center
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Regional Hospital
-
-
Arkansas
-
Hot Springs, Arkansas, Forente stater, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Auburn, California, Forente stater, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Forente stater, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Baldwin Park, California, Forente stater, 91706
- Kaiser Permanente-Baldwin Park
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burbank, California, Forente stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Burlingame, California, Forente stater, 94010
- Mills-Peninsula Medical Center
-
Cameron Park, California, Forente stater, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Castro Valley, California, Forente stater, 94546
- Eden Hospital Medical Center
-
Davis, California, Forente stater, 95616
- Sutter Davis Hospital
-
La Jolla, California, Forente stater, 92093
- UC San Diego Moores Cancer Center
-
Modesto, California, Forente stater, 95355
- Memorial Medical Center
-
Mountain View, California, Forente stater, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Forente stater, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Palo Alto, California, Forente stater, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Forente stater, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Forente stater, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Forente stater, 95816
- Sutter Medical Center Sacramento
-
San Diego, California, Forente stater, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Forente stater, 92108
- Kaiser Permanente-Rio San Diego
-
San Francisco, California, Forente stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Marcos, California, Forente stater, 92078
- Kaiser Permanente-San Marcos
-
Santa Cruz, California, Forente stater, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Forente stater, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Forente stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Forente stater, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Yale University
-
-
Delaware
-
Lewes, Delaware, Forente stater, 19958
- Beebe Medical Center
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Forente stater, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Forente stater, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
Seaford, Delaware, Forente stater, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Forente stater, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
Georgia
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Forente stater, 31404
- Memorial Health University Medical Center
-
Savannah, Georgia, Forente stater, 31404
- Summit Cancer Care-Memorial
-
Savannah, Georgia, Forente stater, 31404
- Low Country Cancer Care
-
-
Idaho
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forente stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forente stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Forente stater, 61701
- OSF Saint Joseph Medical Center
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forente stater, 62902
- Memorial Hospital of Carbondale
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forente stater, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Hinsdale, Illinois, Forente stater, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Mount Vernon, Illinois, Forente stater, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa, Illinois, Forente stater, 61350
- Radiation Oncology of Northern Illinois
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Forente stater, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Forente stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forente stater, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Forente stater, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Forente stater, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forente stater, 62702
- Central Illinois Hematology Oncology Center
-
Springfield, Illinois, Forente stater, 62781
- Springfield Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forente stater, 46202
- Sidney and Lois Eskenazi Hospital
-
Richmond, Indiana, Forente stater, 47374
- Reid Health
-
-
Iowa
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Forente stater, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, Forente stater, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Forente stater, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Forente stater, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Forente stater, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Forente stater, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Forente stater, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Forente stater, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Forente stater, 67905
- Cancer Center of Kansas-Liberal
-
Newton, Kansas, Forente stater, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Forente stater, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Forente stater, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Forente stater, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Forente stater, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Forente stater, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Forente stater, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Forente stater, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Forente stater, 67208
- Associates In Womens Health
-
Winfield, Kansas, Forente stater, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Forente stater, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Forente stater, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Forente stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Forente stater, 40202
- Jewish Hospital
-
Louisville, Kentucky, Forente stater, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Forente stater, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Forente stater, 40165
- Jewish Hospital Medical Center South
-
-
Maine
-
Scarborough, Maine, Forente stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Cancer Center
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Clinic
-
-
Michigan
-
Brownstown, Michigan, Forente stater, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Forente stater, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Forente stater, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forente stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Forente stater, 48334
- Weisberg Cancer Treatment Center
-
Novi, Michigan, Forente stater, 48377
- Henry Ford Medical Center-Columbus
-
West Bloomfield, Michigan, Forente stater, 48322
- Henry Ford West Bloomfield Hospital
-
-
Missouri
-
Bolivar, Missouri, Forente stater, 65613
- Central Care Cancer Center - Bolivar
-
Bonne Terre, Missouri, Forente stater, 63628
- Parkland Health Center-Bonne Terre
-
Branson, Missouri, Forente stater, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Forente stater, 63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City, Missouri, Forente stater, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Forente stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
Sullivan, Missouri, Forente stater, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Forente stater, 59101
- Saint Vincent Healthcare
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Forente stater, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Forente stater, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Forente stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forente stater, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Forente stater, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Forente stater, 68847
- CHI Health Good Samaritan
-
Kearney, Nebraska, Forente stater, 68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln, Nebraska, Forente stater, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Forente stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forente stater, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Forente stater, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Forente stater, 68122
- Hematology and Oncology Consultants PC
-
Papillion, Nebraska, Forente stater, 68046
- Midlands Community Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Camden, New Jersey, Forente stater, 08103
- Cooper Hospital University Medical Center
-
Hackensack, New Jersey, Forente stater, 07601
- Hackensack University Medical Center
-
Voorhees Township, New Jersey, Forente stater, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
New York, New York, Forente stater, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Clinton, North Carolina, Forente stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Clinton, North Carolina, Forente stater, 28328
- Sampson Radiation Oncology
-
Goldsboro, North Carolina, Forente stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Goldsboro, North Carolina, Forente stater, 27534
- Wayne Memorial Hospital
-
Goldsboro, North Carolina, Forente stater, 27534
- Wayne Radiation Oncology
-
Jacksonville, North Carolina, Forente stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Jacksonville, North Carolina, Forente stater, 28546
- Onslow Memorial Hospital
-
-
Ohio
-
Beachwood, Ohio, Forente stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Forente stater, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Forente stater, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Forente stater, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Forente stater, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Forente stater, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Forente stater, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Forente stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forente stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forente stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forente stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forente stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forente stater, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Forente stater, 43215
- Grant Medical Center
-
Columbus, Ohio, Forente stater, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Forente stater, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Forente stater, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Forente stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Forente stater, 43015
- Delaware Radiation Oncology
-
Delaware, Ohio, Forente stater, 43015
- Grady Memorial Hospital
-
Findlay, Ohio, Forente stater, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Forente stater, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Forente stater, 45840
- Orion Cancer Care
-
Franklin, Ohio, Forente stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Forente stater, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Forente stater, 45331
- Wayne Hospital
-
Greenville, Ohio, Forente stater, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Forente stater, 45429
- Kettering Medical Center
-
Kettering, Ohio, Forente stater, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Forente stater, 43130
- Fairfield Medical Center
-
Marietta, Ohio, Forente stater, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Forente stater, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Mayfield Heights, Ohio, Forente stater, 44124
- UH Seidman Cancer Center at Landerbrook Health Center
-
Mentor, Ohio, Forente stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middletown, Ohio, Forente stater, 45042
- Dayton Physicians LLC-Signal Point
-
Mount Vernon, Ohio, Forente stater, 43050
- Knox Community Hospital
-
Newark, Ohio, Forente stater, 43055
- Licking Memorial Hospital
-
Newark, Ohio, Forente stater, 43055
- Newark Radiation Oncology
-
Portsmouth, Ohio, Forente stater, 45662
- Southern Ohio Medical Center
-
Sidney, Ohio, Forente stater, 45365
- Dayton Physicians LLC-Wilson
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Forente stater, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Forente stater, 45373
- Dayton Physicians LLC - Troy
-
Wadsworth, Ohio, Forente stater, 44281
- University Hospitals Sharon Health Center
-
Westerville, Ohio, Forente stater, 43081
- Saint Ann's Hospital
-
Westlake, Ohio, Forente stater, 44145
- UHHS-Westlake Medical Center
-
Zanesville, Ohio, Forente stater, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forente stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forente stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Forente stater, 97420
- Bay Area Hospital
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Forente stater, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Abington, Pennsylvania, Forente stater, 19001
- Jefferson Abington Hospital
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Chadds Ford, Pennsylvania, Forente stater, 19317
- Christiana Care Health System-Concord Health Center
-
Ephrata, Pennsylvania, Forente stater, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Forente stater, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Forente stater, 17331
- WellSpan Medical Oncology and Hematology
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania/Abramson Cancer Center
-
West Reading, Pennsylvania, Forente stater, 19611
- Reading Hospital
-
York, Pennsylvania, Forente stater, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Forente stater, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Boiling Springs, South Carolina, Forente stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
Easley, South Carolina, Forente stater, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forente stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forente stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Forente stater, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Greenville Memorial Hospital
-
Greenville, South Carolina, Forente stater, 29601
- Greenville Health System Cancer Institute-Andrews
-
Greer, South Carolina, Forente stater, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Forente stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57105
- Avera Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
- Memorial Hospital
-
Hixson, Tennessee, Forente stater, 37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Ooltewah, Tennessee, Forente stater, 37363
- Memorial GYN Plus
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- UT MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
South Jordan, Utah, Forente stater, 84009
- South Jordan Health Center
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Inova Fairfax Hospital
-
-
Washington
-
Aberdeen, Washington, Forente stater, 98520
- Providence Regional Cancer System-Aberdeen
-
Anacortes, Washington, Forente stater, 98221
- Cancer Care Center at Island Hospital
-
Bellevue, Washington, Forente stater, 98005
- Swedish Cancer Institute-Eastside Oncology Hematology
-
Bellingham, Washington, Forente stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Forente stater, 98166
- Saint Anne Hospital
-
Centralia, Washington, Forente stater, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Forente stater, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Forente stater, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Forente stater, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Forente stater, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Lacey, Washington, Forente stater, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Forente stater, 98499
- Saint Clare Hospital
-
Longview, Washington, Forente stater, 98632
- PeaceHealth Saint John Medical Center
-
Poulsbo, Washington, Forente stater, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Forente stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forente stater, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Forente stater, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Forente stater, 98104
- Minor and James Medical PLLC
-
Seattle, Washington, Forente stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forente stater, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Forente stater, 98133
- University of Washington Medical Center - Northwest
-
Seattle, Washington, Forente stater, 98133
- Women's Cancer Center of Seattle
-
Shelton, Washington, Forente stater, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Forente stater, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Forente stater, 99218
- Evergreen Hematology and Oncology PS
-
Spokane, Washington, Forente stater, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane Valley, Washington, Forente stater, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Tacoma, Washington, Forente stater, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Forente stater, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Forente stater, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Forente stater, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Forente stater, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Medical College of Wisconsin
-
-
Wyoming
-
Cody, Wyoming, Forente stater, 82414
- Big Horn Basin Cancer Center
-
Cody, Wyoming, Forente stater, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Forente stater, 82801
- Welch Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients must have persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease progression (disease not amendable to curative therapy); NOTE: the following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma and mesonephric carcinoma; histologic confirmation of the original primary tumor is required via the pathology report
-
All patents must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have at least one "target" lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
-
Appropriate for study entry based on the following diagnostic workup:
-
History/physical examination within 28 days prior to registration
-
Imaging of target lesion(s) within 28 days prior to registration
-
Further protocol-specific assessments:
- Recovery from adverse effects of recent surgery, radiotherapy or chemotherapy
- Any other prior therapy directed at the malignant tumor including chemotherapy, biologic/targeted agents and immunologic agents must be discontinued at least three weeks prior to registration
- Investigation agents must be discontinued for at least 30 days prior to registration
- Any prior radiation therapy must be completed at least 4 weeks prior to registration
- At least 4 weeks must have elapsed since any major surgery prior to registration
-
-
Patients must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles); NOTE: patients who have received more than one prior regimen are NOT eligible
-
Performance status of 0 or 1
-
Absolute neutrophil count (ANC) >= 1,500/ul
-
Platelets >= 100,000/ul
-
Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) >= 40 mL/min using Cockcroft-Gault formula
-
Bilirubin =< 1.5 x ULN
-
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
-
Normal thyroid function testing (thyroid stimulating hormone [TSH]) within 14 days prior to registration
-
The patient or a legally authorized representative must provide study-specific informed consent authorization permitting release of personal health information prior to study entry
Exclusion Criteria:
-
Patients who have had prior therapy with nivolumab or with an anti-PD-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
-
Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure and unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Patients who are pregnant or nursing; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding
- Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile or have undergone definitive radiation) do not require contraception
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy of bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL
- WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product
- Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform the treating physician immediately
-
Patients with known brain metastases or leptomeningeal metastases are excluded unless the following conditions are met:
- Metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment is complete (must be confirmed within 28 days prior to the first dose of nivolumab administration)
- There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration
-
Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Patients should be excluded if they have a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IRB), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded; patient with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
- NOTE: patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI) obstruction and/or who require parenteral hydration and/or nutrition
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment (nivolumab)
Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Tumor Response as Assessed by RECIST 1.1 Criteria
Tidsramme: The average of study treatment time was 3.8 months.
|
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1. |
The average of study treatment time was 3.8 months.
|
|
Adverse Events (Grade 3 or Higher) During Treatment Period as Assessed by CTCAE Version 4
Tidsramme: Within 100 days of last protocol treatment
|
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0. |
Within 100 days of last protocol treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival
Tidsramme: Time from study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up.
|
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1. |
Time from study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up.
|
|
Overall Survival
Tidsramme: Time from study entry to time of death or the date of last contact, up to 5 years of follow-up
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from study entry to time of death or the date of last contact, up to 5 years of follow-up
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Tumor Expressions of PD-1 and PD-L1 in Tumor Infiltrating Lymphocytes and Cervical Cancer Cells
Tidsramme: Up to 5 years
|
Spearman's correlation coefficient will be used to explore the associations of tumor expressions of PD-L1, PD-1 and other interested biomarkers with tumor response. Cox proportional hazards (PH) model will be utilized to evaluate the associations of these tumor expressions with PFS and OS. These expressions may also be dichotomized into high versus low values (cut at the median). Log-rank tests will be used to assess the associations of these dichotomized tumor expressions with PFS and OS. The corresponding hazard rations will be estimated by Cox PH models. |
Up to 5 years
|
|
Immune Infiltration Related Biomarkers (i.e., CD4+, CD8+, FoxP3) in Tumor Specimens
Tidsramme: Up to 5 years
|
Immune infiltration related biomarkers (i.e., CD4+, CD8+, FoxP3) in tumor specimens will be associated with objective tumor response, PFS and OS in nivolumab-treated patients. |
Up to 5 years
|
|
Change in the Immune Response to HPV 16/18/31/35/45 E7 Antigen in Peripheral Blood Lymphocytes and Serum
Tidsramme: Baseline to up to 5 years
|
Wilcoxon signed rank test (for interval or ordinal data) or McNemar's test (for binary data) may be utilized to examine whether the study treatment will change immune response to HPV 16/18/31/35/45 E7 antigen in peripheral blood lymphocytes and serum by changes in the measures of pre- and post-treatment immune response to HPV 16/18/31/35/45 E7. |
Baseline to up to 5 years
|
|
Change in the CTC Count
Tidsramme: Baseline to up to 12 weeks
|
Change in the CTC count and whether the CTC count is associated with objective response, PFS and OS in nivolumab-treated patients will be evaluated. |
Baseline to up to 12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Alessandro D Santin, NRG Oncology
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Genitale neoplasmer, kvinnelige
- Livmor livmorhalssykdommer
- Uterine neoplasmer
- Uterine cervikale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Nivolumab
Andre studie-ID-numre
- NCI-2014-02021
- U10CA180868 (U.S. NIH-stipend/kontrakt)
- NCI-2014-02021 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- PNRG-GY002_A01PAMDREVW01
- NRG-GY002 (Annen identifikator: CTEP)
- NRG-GY002
- NRG-GY002 (Annen identifikator: NRG Oncology)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .